Objectives: To determine the changes in the levels of Malondialdehyde (MDA) and antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) in autistic children receiving melatonin supplementation to evaluate its antioxidant role in autism. Methods: A follow-up study was carried out in the Department of therapeutics and clinical pharmacy, Baghdad College of Medical Sciences, Baghdad - Iraq. The study was performed on 55 autistic children who had recruited from several private institutions specialized in autistic children care, Baghdad, Iraq between June 2018 and November 2018. The levels of melatonin, MDA, SOD and CAT were measured in the serum of 55 patients before and after receiving melatonin supplementation for three months. Results: The results revealed statistically significant differences in the levels of melatonin, MDA, SOD and CAT between patients before and after receiving melatonin supplement. Furthermore, melatonin levels showed significant positive correlations with both SOD and CAT in addition to a significant positive correlation between SOD and CAT while MDA levels showed significant negative correlations with melatonin, SOD and CAT in autistic patients before and after receiving the supplement. Conclusions: Melatonin levels, CAT and SOD activity showed to be improved significantly by melatonin supplementation with a concomitant reduction in the levels of MDA as an indicator of a decrease in an oxidative stress in autistic children.
Cite this article:
Mohammed B. Mohammed, Yasir S J Alrubaye. The Oxidative status in Children with Autism receiving Melatonin. Research Journal of Pharmacy and Technology. 2022; 15(1):338-2. doi: 10.52711/0974-360X.2022.00055
Mohammed B. Mohammed, Yasir S J Alrubaye. The Oxidative status in Children with Autism receiving Melatonin. Research Journal of Pharmacy and Technology. 2022; 15(1):338-2. doi: 10.52711/0974-360X.2022.00055 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-1-55
1. Abdulamir HA, Abdul-Rasheed OF, Abdulghani EA. Serotonin and serotonin transporter levels in autistic children. Saudi Med J 2018;39:487-94.
2. Abdulamir HA, Al-Awadi SJA, Abdul-Rasheed OF. The correlation of single nucleotide polymorphism in oxytocin and oxytocin receptor genes and the serum oxytocin level in the Iraqi children with autism. Int J Pharm Bio Sci 2016; 7: (B) 668 - 75
3. Yadav S. Autism Spectrum Disorder- A Review. Int. J. Nur. Edu. and Research. 2016; 4(2): 223-226.
4. Hasan AA. A Descriptive Study among Children suffering from Autism in Baghdad, Iraq. Research J. Pharm. and Tech. 2017; 10(6): 1919-1923.
5. Dhariyal RS, Kimothi V, Singh S. A Review on Autism. Res. J. Pharmacology and Pharmacodynamics.2019; 11(2):76-80.
6. Abdulamir HA, Abdul-Rasheed OF, Abdulghani EA. Low oxytocin and melatonin levels and their possible role in the diagnosis and prognosis in Iraqi autistic children. Saudi Med J 2016; 37: 29-36.
7. Son CM, Min BI, Moon HW. The Effects of Combined Exercise on Blood Lipids and Melatonin in Developmental Disorder Students. Research J. Pharm. and Tech 2018; 11(12): 5543-5647.
8. Carrillo-Vico A, Lardone PJ, Alvarez-Sanchez N, Rodriguez-Rodriguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci 2013; 14: 8638-83.
9. Tordjman S, Anderson GM, Cohen D, Kermarrec S, Carlier M, Touitou Y, et al. Presence of autism, hyperserotonemia, and severe expressive language impairment in Williams-Beuren syndrome. Mol Autism 2013; 4: 29.
10. Saha D, Tamrakar A. Xenobiotics, Oxidative Stress, Free Radicals Vs. Antioxidants: Dance Of Death to Heaven’s Life. Asian J. Res. Pharm. Sci. 2011; 1(2)36-38.
11. Vaishali M. Antioxidants in Health and Diseases. Research J. Pharm. and Tech. 2014; 7(4)489-493.
12. Patlevič P, Vašková J, Švorc P, Vaško L, Švorc P. Reactive oxygen species and antioxidant defense in human gastrointestinal diseases. Integr Med Res 2016;5:250-8.
13. Vadivelan R, Dhanabal SP, Raja Rajeswari, Shanish A, Elango K, Suresh B. Oxidative Stress in Diabetes- A Key Therapeutic Agent. Research J. Pharmacology and Pharmacodynamics. 2010; 2(3): 221-227.
14. Sheng Y, Abreu IA, Cabelli DE, et al. Superoxide Dismutases and Superoxide Reductases. Chemical Reviews 2014;114:3854-918.
15. Suresh PK, Sah AK, Daharwal SJ. Role of free radicals in ocular diseases: An overview. Research J. Pharm. and Tech. 2014;7(11)1330-1344.
16. Chakraborty P, Kumar S, Dutta D, Gupta V. Role of Antioxidants in Common Health Diseases. Research J. Pharm. and Tech. 2009;2(2) 238-244.
17. Mahurkar N, Hasan SMSU, Malpani AA, Chetan M. Influence of Single and Multiple Dose Regimen of Melatonin, Rabeprazole and their Combination in Gastroprotection in Pylorus Ligated Albino Rats. Research J. Pharm. and Tech. 2013; 6(5)562-568.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Publishing; 2013.
19. Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract 2010; 15: 625-32.
20. Hernández DQ, Cruz AL, González SB, Vila DT, Robert YC, Forment GR, Tamargo barbeito TO. Variation of the REDOX Status in Patients with Primary Autism after Antioxidant Therapy. J Neurol Transl Neurosci 2017:5: 1085.
21. Altun H, Şahin N, Kurutaş EB, Karaaslan U, Sevgen FH, Fındıklı E. Assessment of malondialdehyde levels, superoxide dismutase, and catalase activity in children with autism spectrum disorders, Psychiatry and Clinical Psychopharmacology 2018; DOI: 10.1080/24750573.2018.1470360
22. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum disorder. Sleep Med 2010;11:659-64.
23. Sánchez-Barceló EJ, Mediavilla MD, Reiter RJ. Clinical uses of melatonin in pediatrics. Int J Pediatr 2011;2011:892624.
24. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl) 2014; 231: 1201-16.
25. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal. Res 2004; 36: 1-9.
26. Reiter RJ Tan D.X, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci 2000;7: 444-58.
27. Tan DX., Chen L, D, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1:57-60.
28. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal. Res 2013; 54: 245-57.
29. Büyükavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savaşan S. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol 2006 Feb;20:73-9.
30. Galano A, Tan DX, Reiter RJ. On the free radicals scavenging activities of melatonin’s metabolites, AFMK and AMK. JPineal Res 2013; 54:245-57